Relmada Therapeutics Inc (NASDAQ:RLMD) has a beta value of 0.38 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $11.96M, closed the recent trade at $0.40 per share which meant it gained $0.03 on the day or 8.96% during that session. The RLMD stock price is -1705.0% off its 52-week high price of $7.22 and 12.5% above the 52-week low of $0.35. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.84 million shares traded. The 3-month trading volume is 758.45K shares.
The consensus among analysts is that Relmada Therapeutics Inc (RLMD) is Sell stock at the moment, with a recommendation rating of 3.00. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
Sporting 8.96% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RLMD stock price touched $0.40 or saw a rise of 20.37%. Year-to-date, Relmada Therapeutics Inc shares have moved -90.34%, while the 5-day performance has seen it change -16.86%. Over the past 30 days, the shares of Relmada Therapeutics Inc (NASDAQ:RLMD) have changed -87.34%. Short interest in the company has seen 1.26 million shares shorted with days to cover at 4.52.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 94.29% from the levels at last check today. The projected low price target is $2.0 while the price target rests at a high of $8.0. In that case, then, we find that the latest price level in today’s session is -1900.0% off the targeted high while a plunge would see the stock gain -400.0% from the levels at last check today.
Relmada Therapeutics Inc (RLMD) estimates and forecasts
Figures show that Relmada Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -86.67% over the past 6 months, with this year growth rate of 16.77%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -2.94% over the past 5 years.
RLMD Dividends
Relmada Therapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
Insiders own 8.04% of the company shares, while shares held by institutions stand at 46.06% with a share float percentage of 50.09%. Investors are also buoyed by the number of investors in a company, with Relmada Therapeutics Inc having a total of 92.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 1.26 million shares worth more than $3.77 million. As of 2024-06-30, VANGUARD GROUP INC held 4.1706% of shares outstanding.
The other major institutional holder is DEEP TRACK CAPITAL, LP, with the holding of over 1.23 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.7 million and represent 4.0979% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Franklin Strategic Series-Franklin Biotechnology Discove. As of Sep 30, 2024, the former fund manager holds about 8.61% shares in the company for having 851.92 shares of worth $0.34 million while later fund manager owns 374.03 shares of worth $0.15 million as of Jul 31, 2024, which makes it owner of about 3.78% of company’s outstanding stock.
